Impurity Control Strategy

Impurity Control Strategy is a systematic, science- and risk-based framework within pharmaceutical development and manufacturing that defines and integrates the procedures, specifications, and controls required to detect, evaluate, and consistently limit process- and product-related impurities in drug substances and drug products to acceptable levels throughout their lifecycle.

130

Publications

4.7K

Citations

647

Authors

189

Institutions

Publications per year

2017–2026

30

Authors

647

  1. AT
    Andrew Teasdale

    AstraZeneca (United Kingdom), United Kingdom

    5 publications · 220 citations

    6

    h-index

  2. MJ
    Michael J. Burns

    University of York, United Kingdom

    3 publications · 80 citations

    5

    h-index

  3. EL
    Eric L. Elliott

    Takeda (United States), United States

    3 publications · 77 citations

    4

    h-index

  4. SG
    Sándor Gǒrög

    Gedeon Richter (Hungary), Hungary

    4 publications · 313 citations

    4

    h-index

  5. BA
    Bernard A. Olsen

    Eli Lilly (United States), United States

    4 publications · 145 citations

    4

    h-index

1–5 of 647

Venues

  1. Organic Process Research & Development

    19 publications · 587 citations

    13

    h-index

  2. 13

    h-index

  3. Journal of Nuclear Materials

    14 publications · 319 citations

    12

    h-index

  4. Journal of Crystal Growth

    4 publications · 142 citations

    4

    h-index

  5. TrAC Trends in Analytical Chemistry

    4 publications · 300 citations

    4

    h-index

1–5